ResearchPod Summary
Phospholipase D3 (PLD3) and PLD4 are endolysosomal exonucleases that degrade single-stranded DNA and RNA, playing a key role in regulating innate immune responses by modulating toll-like receptors. Because polymorphisms in these enzymes are linked to Alzheimer’s, rheumatoid arthritis, and systemic sclerosis, there is significant interest in developing small-molecule modulators as potential immunotherapies. While previous efforts successfully identified modulators for PLD3, they failed to find selective compounds for PLD4. This study aimed to bridge that gap by screening an expanded diversity library to identify chemical scaffolds capable of selectively targeting PLD4.
The authors conducted a high-throughput screen of 45,760 compounds using a refined fluorogenic assay. By employing a counterscreen to eliminate compounds that interfere with the fluorescence signal, they minimized false positives. After filtering the primary hits through ADME-Tox criteria and performing structure-activity relationship (SAR) clustering, they identified 14 candidates. Of these, four compounds (one inhibitor and three activators) showed consistent, selective potency for PLD4 with values below 50 μM.
To understand how these hits influence enzyme function, the researchers performed detailed steady-state kinetic modeling. The identified inhibitor (I3) exhibited competitive inhibition, consistent with substrate-mimetic activity. Conversely, the three activators (A2, A3, and A4) followed a mixed activation model, preferentially binding to the enzyme-substrate complex. These findings suggest that the activators lower the Michaelis constant (Km) and increase the turnover rate (kcat), providing a robust mechanistic foundation for future drug development efforts targeting PLD4-related pathways.
The identification of selective PLD4 modulators provides researchers with new chemical tools to probe the enzyme's specific role in immune regulation. Because PLD4 is highly expressed in dendritic and myeloid cells, these compounds could serve as a basis for developing targeted therapies for autoimmune disorders and cancer where PLD4 activity is known to be altered.
AI-generated third-party summary by ResearchPod. Not official content or an endorsement by the paper authors or affiliated organizations.